Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Mereo BioPharma Group plcNASDAQ: MREO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $171K fell 36.7% year over year, behind the +9.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 76.3% from the prior quarter. Over 3 fiscal years it compounded at -11.2% a year.

Context

  • Depreciation & amortization amounted to 124.4% of revenue in FY2025.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -36.7% toward the trailing-twelve-month pace of +9.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$171K-76.3% QoQ
Last fiscal yearDec 2025
$622K-42.8% YoY
LTMMar 2026
$1.18M+9.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.7%——
1 year-42.8%——
3-year CAGR-11.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
622K USD
Year-over-year change
-42.8%
4-year CAGR
-8.0%

Depreciation & Amortization vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.0% is the 4th highest of 10, against a peer median of +3.1%.
  • Depreciation & amortization amounts to 236.0% of revenue for MREO, versus a peer median of 58.6%.
MREO Competitors
Depreciation & Amortization for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.25B USD+83349.3%+52.5%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.5M CHF+15.5%+0.4%69.9%
IMMPImmutep LimitedFY2025A$2.39M AUD+5.6%+5.0%47.4%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$1.99M USD-1.7%-30.8%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$1.65M USD-23.4%+19.6%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.18M USD+9.0%-11.2%236.0%
SLNSilence Therapeutics plcLTM Mar 2026$885K USD—-2.3%96.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$749K USD-23.9%+2.8%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K USD+19.3%-0.6%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
Peer median (excluding MREO) —+3.1%+0.7%58.6%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.